

# Harvey D White

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1298926/publications.pdf>

Version: 2024-02-01

461  
papers

67,835  
citations

2215

99  
h-index

718

252  
g-index

474  
all docs

474  
docs citations

474  
times ranked

40971  
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	1.6	3,378
2	Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2634-2653.	1.6	2,755
3	Third Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2012, 126, 2020-2035.	1.6	2,722
4	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	2.2	2,687
5	Third universal definition of myocardial infarction. <i>Nature Reviews Cardiology</i> , 2012, 9, 620-633.	13.7	2,615
6	Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>New England Journal of Medicine</i> , 1999, 341, 625-634.	27.0	2,596
7	Fourth Universal Definition of Myocardial Infarction (2018). <i>Journal of the American College of Cardiology</i> , 2018, 72, 2231-2264.	2.8	2,285
8	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	27.0	2,211
9	Fourth Universal Definition of Myocardial Infarction (2018). <i>Circulation</i> , 2018, 138, e618-e651.	1.6	1,858
10	Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. <i>European Heart Journal</i> , 2007, 28, 2525-2538.	2.2	1,856
11	Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2004, 351, 1285-1295.	27.0	1,712
12	Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2173-2195.	2.8	1,557
13	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	27.0	1,508
14	Bivalirudin for Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2006, 355, 2203-2216.	27.0	1,367
15	Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1307.	7.4	1,166
16	Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. <i>Lancet</i> , 2002, 359, 189-198.	13.7	944
17	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2011, 365, 699-708.	27.0	918
18	Impact of Major Bleeding on 30-Day Mortality and Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1362-1368.	2.8	776

#	ARTICLE	IF	CITATIONS
19	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	27.0	765
20	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010, 376, 1233-1243.	13.7	725
21	Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 45-54.	7.4	702
22	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2012, 366, 20-33.	27.0	701
23	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. <i>New England Journal of Medicine</i> , 2013, 368, 1303-1313.	27.0	695
24	Acute Coronary Care in the Elderly, Part I. <i>Circulation</i> , 2007, 115, 2549-2569.	1.6	693
25	Effect of Intravenous Streptokinase on Left Ventricular Function and Early Survival after Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 1987, 317, 850-855.	27.0	646
26	Coronary Intervention for Persistent Occlusion after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2006, 355, 2395-2407.	27.0	635
27	One-Year Survival Following Early Revascularization for Cardiogenic Shock. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 190.	7.4	575
28	Early Revascularization and Long-term Survival in Cardiogenic Shock Complicating Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2511.	7.4	572
29	Intravenous Platelet Blockade with Cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2330-2341.	27.0	560
30	Acute myocardial infarction. <i>Lancet, The</i> , 2008, 372, 570-584.	13.7	557
31	Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2006, 354, 1477-1488.	27.0	556
32	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , 2019, 51, 957-972.	21.4	549
33	Platelet Inhibition with Cangrelor in Patients Undergoing PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2318-2329.	27.0	533
34	Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control. <i>Archives of Internal Medicine</i> , 2007, 167, 239.	3.8	527
35	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	13.7	512
36	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	27.0	510

#	ARTICLE	IF	CITATIONS
37	Acute Coronary Care in the Elderly, Part II. <i>Circulation</i> , 2007, 115, 2570-2589.	1.6	489
38	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1702-1711.	27.0	467
39	Link Between the Angiographic Substudy and Mortality Outcomes in a Large Randomized Trial of Myocardial Reperfusion. <i>Circulation</i> , 1995, 91, 1923-1928.	1.6	416
40	Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 979.	7.4	393
41	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1006.	7.4	375
42	Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. <i>Lancet, The</i> , 2007, 369, 907-919.	13.7	367
43	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. <i>American Heart Journal</i> , 2014, 168, 682-689.e1.	2.7	365
44	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 654-664.	2.9	329
45	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1582-1590.	2.2	329
46	Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2006, 355, 1006-1017.	27.0	325
47	Pathobiology of Troponin Elevations. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2406-2408.	2.8	320
48	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. <i>European Heart Journal</i> , 2009, 30, 1457-1466.	2.2	315
49	Third Universal Definition of Myocardial Infarction. <i>Global Heart</i> , 2012, 7, 275.	2.3	309
50	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	2.8	296
51	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. <i>Lancet, The</i> , 2013, 382, 1981-1992.	13.7	286
52	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. <i>Nature Genetics</i> , 2018, 50, 26-41.	21.4	286
53	Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1380-1386.	2.8	274
54	Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 591.	7.4	266

#	ARTICLE	IF	CITATIONS
55	Importance of frailty in patients with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 1726-1731.	2.2	239
56	Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. <i>American Heart Journal</i> , 2004, 148, 764-775.	2.7	231
57	Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and Aspirin<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 55.	7.4	218
58	Antithrombotic Strategies in Patients With Acute Coronary Syndromes Undergoing Early Invasive Management. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2497.	7.4	217
59	Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction.. <i>Circulation</i> , 1994, 89, 61-67.	1.6	212
60	Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.	2.8	212
61	Comparison of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting After Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>Circulation</i> , 2005, 112, 1992-2001.	1.6	210
62	Evaluation of paradoxical beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: Mechanism of the â€œsmoker's paradoxâ€œfrom the GUSTO-I trial, with angiographic insights. <i>Journal of the American College of Cardiology</i> , 1995, 26, 1222-1229.	2.8	209
63	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	11.4	207
64	Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO). <i>Circulation</i> , 1997, 96, 2155-2161.	1.6	207
65	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018, 379, 1107-1117.	27.0	205
66	Thrombolysis for Acute Myocardial Infarction. <i>Circulation</i> , 1998, 97, 1632-1646.	1.6	192
67	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	2.8	186
68	Inflammatory Biomarkers Interleukinâ€œ6 and Câ€œReactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) Tj ETQq0 0 0 rgBT30 Overlock10 Tf 50 2		
69	Prognostic Significance of Periprocedural Versus Spontaneously Occurring Myocardial Infarction After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 477-486.	2.8	178
70	Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 245-253.	2.3	171
71	Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and gender*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 433-439.	4.7	171
72	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017, 38, ehw525.	2.2	164

#	ARTICLE	IF	CITATIONS
73	After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study.. Circulation, 1993, 88, 2097-2103.	1.6	157
74	Long-Term Survival and Valve-Related Complications in Young Women With Cardiac Valve Replacements. Circulation, 1999, 99, 2669-2676.	1.6	157
75	Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38. Circulation, 2009, 119, 2758-2764.	1.6	155
76	Thrombolytic therapy in the elderly. Lancet, The, 2000, 356, 2028-2030.	13.7	154
77	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 74, 1167-1176.	2.8	154
78	Prognosis of Patients With Non-ST-Segment Elevation Myocardial Infarction and Nonobstructive Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2014, 7, 285-293.	3.9	151
79	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling. Journal of the American College of Cardiology, 2016, 68, 1169-1178.	2.8	133
80	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology, 2019, 73, 387-396.	2.8	131
81	Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization. Circulation, 2013, 128, 823-833.	1.6	130
82	Clinical implications of the new definition of myocardial infarction. British Heart Journal, 2004, 90, 99-106.	2.1	128
83	Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation, 2016, 134, 1314-1324.	1.6	127
84	Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2002, 288, 2130.	7.4	125
85	Advanced Age, Antithrombotic Strategy, and Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 53, 1021-1030.	2.8	125
86	Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Annals of Thoracic Surgery, 2004, 77, 925-931.	1.3	121
87	Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: The Targeted platelet Inhibition to Clarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY) Trial. JAMA - Journal of the American Medical Association, 2011, 306, 1034-1042.	2.7	120
88	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal, 2020, 41, 4245-4255.	2.2	117
89	Stent deformation following simulated side-branch dilatation: A comparison of five stent designs. Catheterization and Cardiovascular Interventions, 1999, 47, 258-264.	1.7	116
90	Functional Status and Quality of Life After Emergency Revascularization for Cardiogenic Shock Complicating Acute Myocardial Infarction. Journal of the American College of Cardiology, 2005, 46, 266-273.	2.8	113

#	ARTICLE	IF	CITATIONS
91	Long-term risk stratification for survivors of acute coronary syndromes. Journal of the American College of Cardiology, 2001, 38, 56-63.	2.8	112
92	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 T patients with coronary heart disease. American Heart Journal, 2010, 160, 655-661.e2.	2.7	111
93	Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 231-242.	1.0	110
94	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019, 140, 103-112.	1.6	107
95	Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheterization and Cardiovascular Interventions, 2007, 69, 73-83.	1.7	106
96	Prognostic differences between different types of bundle branch block during the early phase of acute myocardial infarction: insights from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. European Heart Journal, 2006, 27, 21-28.	2.2	104
97	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. Circulation, 2020, 141, 1608-1617.	1.6	104
98	2011 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand guidelines for the management of acute coronary syndromes (ACS) 2006. Heart Lung and Circulation, 2011, 20, 487-502.	0.4	103
99	Diagnostic and Therapeutic Implications of Type 2 Myocardial Infarction: Review and Commentary. American Journal of Medicine, 2014, 127, 105-108.	1.5	103
100	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 T	1.6	102
101	Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction. Circulation, 2005, 112, 3391-3399.	1.6	101
102	Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. European Heart Journal, 2016, 37, 1993-2001.	2.2	101
103	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiology, 2019, 4, 273.	6.1	100
104	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clinical Chemistry, 2017, 63, 325-333.	3.2	97
105	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. Journal of the American College of Cardiology, 2017, 70, 813-826.	2.8	95
106	D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease. Circulation, 2018, 138, 712-723.	1.6	93
107	Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 63, 619-629.	2.8	92
108	Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction. JACC: Heart Failure, 2014, 2, 159-165.	4.1	91

#	ARTICLE	IF	CITATIONS
109	Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. <i>European Heart Journal</i> , 2007, 28, 1066-1071.	2.2	89
110	Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. <i>American Heart Journal</i> , 2012, 163, 182-190.e4.	2.7	89
111	Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. <i>Nature Genetics</i> , 2019, 51, 452-469.	21.4	89
112	Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. <i>American Heart Journal</i> , 2006, 152, 1042-1050.	2.7	85
113	Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2005, 149, 217-226.	2.7	83
114	Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. <i>European Heart Journal</i> , 2014, 35, 2516-2523.	2.2	83
115	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019, 140, 2054-2062.	1.6	83
116	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. <i>American Journal of Human Genetics</i> , 2016, 99, 40-55.	6.2	82
117	Myocardial Infarction in the ISCHEMIA Trial. <i>Circulation</i> , 2021, 143, 790-804.	1.6	81
118	A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1346-1354.	2.8	79
119	Selection of thrombolytic therapy for individual patients: Development of a clinical model. <i>American Heart Journal</i> , 1997, 133, 630-639.	2.7	77
120	Study design and rationale for the Stabilization of pLaques using Darapladib Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. <i>American Heart Journal</i> , 2011, 162, 613-619.e1.	2.7	77
121	Patients With Prolonged Ischemic Chest Pain and Presumed-New Left Bundle Branch Block Have Heterogeneous Outcomes Depending on the Presence of ST-Segment Changes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 29-38.	2.8	74
122	Safety and Efficacy of Switching From Either Unfractionated Heparin or Enoxaparin to Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Invasive Strategy. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1734-1741.	2.8	74
123	Impact of Collateral Flow to the Occluded Infarct-Related Artery on Clinical Outcomes in Patients With Recent Myocardial Infarction: A Report From the Randomized Occluded Artery Trial. <i>Circulation</i> , 2010, 121, 2724-2730.	1.6	74
124	Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2008, 52, 807-814.	2.8	72
125	Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet InhibitiON PHOENIX trial. <i>American Heart Journal</i> , 2012, 163, 768-776.e2.	2.7	72
126	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. <i>PLoS Medicine</i> , 2021, 18, e1003513.	8.4	70



#	ARTICLE	IF	CITATIONS
127	Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2. <i>Lancet</i> , The, 2006, 367, 2061-2067.	13.7	68
128	Physical activity in patients with stable coronary heart disease: an international perspective. <i>European Heart Journal</i> , 2013, 34, 3286-3293.	2.2	67
129	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2135-2144.	2.8	66
130	aVR ST elevation: an important but neglected sign in ST elevation acute myocardial infarction. <i>European Heart Journal</i> , 2010, 31, 1845-1853.	2.2	65
131	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 391.	6.1	65
132	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2819-2828.	2.8	64
133	Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: A substudy of the GUSTO-III trial. <i>American Heart Journal</i> , 2002, 144, 81-88.	2.7	63
134	Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. <i>European Heart Journal</i> , 2008, 29, 462-471.	2.2	63
135	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	2.2	63
136	Risk Stratification of Patients With Acute Anterior Myocardial Infarction and Right Bundle-Branch Block. <i>Circulation</i> , 2006, 114, 783-789.	1.6	61
137	Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long-Term Coronary Events Following Myocardial Infarction or Unstable Angina. <i>Journal of the American College of Cardiology</i> , 2014, 63, 345-354.	2.8	61
138	Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction.. <i>Heart</i> , 1990, 64, 177-181.	2.9	60
139	Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 678-685.	1.8	60
140	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. <i>American Journal of Human Genetics</i> , 2016, 99, 8-21.	6.2	60
141	White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin. <i>Circulation</i> , 2005, 111, 1756-1762.	1.6	59
142	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	2.8	58
143	High-Risk Patients With Acute Coronary Syndromes Treated With Low-Molecular-Weight or Unfractionated Heparin. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2594.	7.4	57
144	Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. <i>Journal of Internal Medicine</i> , 2018, 283, 83-92.	6.0	57

#	ARTICLE	IF	CITATIONS
145	Design and methodology of the Occluded Artery Trial (OAT). <i>American Heart Journal</i> , 2005, 150, 627-642.	2.7	56
146	GISSI-2 and the heparin controversy. <i>Lancet</i> , The, 1990, 336, 297-298.	13.7	51
147	Rheumatic Heart Disease in Indigenous Populations. <i>Heart Lung and Circulation</i> , 2010, 19, 273-281.	0.4	51
148	Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. <i>International Journal of Cardiology</i> , 2013, 167, 1134-1140.	1.7	51
149	Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 1121-1129.	5.3	51
150	Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004755.	2.2	51
151	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020, 41, 2248-2258.	2.2	51
152	Significance of Atrial Fibrillation During Acute Myocardial Infarction, and its Current Management: Insights from the GUSTO-3 Trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 201-207.	1.0	50
153	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. <i>American Journal of Human Genetics</i> , 2016, 99, 22-39.	6.2	50
154	Persistent psychological distress and mortality in patients with stable coronary artery disease. <i>Heart</i> , 2017, 103, 1860-1866.	2.9	50
155	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 162-171.	2.8	50
156	Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2309-2316.	2.8	49
157	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10,854 patients from the CHAMPION PHOENIX trial. <i>European Heart Journal</i> , 2018, 39, 4112-4121.	2.2	49
158	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	2.8	49
159	The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design. <i>American Heart Journal</i> , 2019, 208, 11-20.	2.7	49
160	Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JACC: Heart Failure</i> , 2013, 1, 223-229.	4.1	48
161	Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease. <i>Circulation</i> , 2016, 133, 1851-1860.	1.6	48
162	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2297-2308.	2.8	48

#	ARTICLE	IF	CITATIONS
163	Changes in Lipoproteinâ€Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Longâ€term Intervention with Pravastatin in Ischemic Disease Study. <i>Journal of the American Heart Association</i> , 2013, 2, e000360.	3.7	47
164	Cangrelor With and Without Glycoproteinâ€IIb/IIIa Inhibitors inâ€Patientsâ€Undergoing Percutaneousâ€Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 176-185.	2.8	47
165	Applying the open artery theory: use of predictive survival markers. <i>European Heart Journal</i> , 1998, 19, 1132-1139.	2.2	46
166	Clinical implications of the Third Universal Definition of Myocardial Infarction. <i>Heart</i> , 2014, 100, 424-432.	2.9	46
167	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2021, 143, 1109-1122.	1.6	46
168	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. <i>European Heart Journal</i> , 2017, 38, 2813-2822.	2.2	45
169	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019, 40, 2801-2809.	2.2	45
170	Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial. <i>Journal of General Internal Medicine</i> , 2008, 23, 310-316.	2.6	44
171	Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial. <i>International Journal of Cardiology</i> , 2010, 139, 123-133.	1.7	44
172	The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 384-392.	2.2	44
173	Diagnosis of MI after CABG with high-sensitivity troponin T and new ECG or echocardiogram changes: relationship with mortality and validation of the Universal Definition of MI. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 323-333.	1.0	44
174	Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). <i>American Heart Journal</i> , 2014, 168, 588-596.	2.7	44
175	Lipoproteinâ€Associated Phospholipase A <sub>2</sub> Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	44
176	Usefulness of the presenting electrocardiogram in predicting successful reperfusion with Streptokinase in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1999, 83, 164-168.	1.6	43
177	Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. <i>JACC: Heart Failure</i> , 2014, 2, 335-343.	4.1	43
178	Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 443-454.	1.0	43
179	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021, 6, 1440.	6.1	43
180	Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. <i>International Journal of Cardiology</i> , 2015, 201, 499-507.	1.7	42

#	ARTICLE	IF	CITATIONS
181	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , 2021, 99, 926-939.	5.2	42
182	Relationship of QRS duration at baseline and changes over 60 min after fibrinolysis to 30-day mortality with different locations of ST elevation myocardial infarction: results from the Hirulog and Early Reperfusion or Occlusion-2 trial. <i>Heart</i> , 2008, 95, 276-282.	2.9	41
183	Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 771-778.	1.8	41
184	Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1048-1057.	2.8	40
185	Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. <i>European Heart Journal</i> , 2003, 24, 172-181.	2.2	39
186	Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends. <i>Journal of the American College of Cardiology</i> , 2013, 62, 242-251.	2.8	39
187	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2015, 132, 1871-1879.	1.6	39
188	Tooth loss is independently associated with poor outcomes in stable coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 839-846.	1.8	39
189	Candesartan and heart failure: the allure of CHARM. <i>Lancet, The</i> , 2003, 362, 754-755.	13.7	38
190	Diagnostic application of the universal definition of myocardial infarction in the intensive care unit. <i>Current Opinion in Critical Care</i> , 2008, 14, 543-548.	3.2	38
191	Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1083-1091.	2.9	38
192	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1905-1913.	2.9	38
193	Adherence and outcomes: it's more than taking the pills. <i>Lancet, The</i> , 2005, 366, 1989-1991.	13.7	36
194	Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. <i>European Heart Journal</i> , 2008, 29, 1827-1833.	2.2	36
195	Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: Results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. <i>American Heart Journal</i> , 2012, 163, 563-571.	2.7	36
196	Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial. <i>European Heart Journal</i> , 2013, 34, 1723-1731.	2.2	36
197	Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?. <i>Lancet, The</i> , 2003, 362, 755-757.	13.7	35
198	International variation in the use of evidence-based medicines for acute coronary syndromes. <i>European Heart Journal</i> , 2003, 24, 2133-2141.	2.2	35

#	ARTICLE	IF	CITATIONS
199	A randomized trial evaluating the effects of change in dairy food consumption on cardio-metabolic risk factors. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1376-1386.	1.8	35
200	Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 424-433.	2.9	35
201	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2016, 67, 936-947.	2.8	35
202	State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease. <i>Clinical Chemistry</i> , 2017, 63, 165-176.	3.2	35
203	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. <i>European Heart Journal</i> , 2020, 41, 4114-4123.	2.2	35
204	Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage. <i>Circulation</i> , 2010, 121, 853-862.	1.6	34
205	Long-Term Effects of Percutaneous Coronary Intervention of the Totally Occluded Infarct-Related Artery in the Subacute Phase After Myocardial Infarction. <i>Circulation</i> , 2011, 124, 2320-2328.	1.6	34
206	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. <i>Heart</i> , 2017, 103, 1168-1176.	2.9	34
207	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
208	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 33-43.	1.8	33
209	Universal MI Definition Update for Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2014, 16, 492.	2.9	32
210	Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: Insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an international randomized Evaluation (STEEPLE) trial. <i>American Heart Journal</i> , 2010, 159, 110-116.	2.7	31
211	Prognostic Significance of Coronary Thrombus in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 769-777.	2.9	31
212	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions. <i>Circulation</i> , 2016, 134, 723-733.	1.6	31
213	Relationship between initial white blood cell counts, stage of acute myocardial infarction evolution at presentation, and incidence of Thrombolysis In Myocardial Infarction-3 flow after streptokinase. <i>American Heart Journal</i> , 2003, 145, 95-102.	2.7	30
214	Systems of Care. <i>Circulation</i> , 2008, 118, 219-222.	1.6	30
215	Prognostic Value of Lead V 1 ST Elevation During Acute Inferior Myocardial Infarction. <i>Circulation</i> , 2010, 122, 463-469.	1.6	30
216	Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions. <i>American Heart Journal</i> , 2011, 161, 450-461.	2.7	30

#	ARTICLE	IF	CITATIONS
217	Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non- $\sigma$ -ST-Segment Elevation Acute Coronary Syndrome Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 357-367.	2.2	30
218	Ruling-In Myocardial Injury and Ruling-Out Myocardial Infarction With the European Society of Cardiology 1-Hour Algorithm. <i>Circulation</i> , 2016, 134, 1542-1545.	1.6	29
219	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2379-2388.	4.4	29
220	Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e010641.	3.7	29
221	Cardiovascular disease on a global scale: defining the path forward for research and practice. <i>European Heart Journal</i> , 2007, 28, 2678-2684.	2.2	28
222	A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. <i>Heart</i> , 2013, 99, 1282-1287.	2.9	28
223	Thrombolytic therapy for patients with myocardial infarction presenting after six hours. <i>Lancet</i> , The, 1992, 340, 221-222.	13.7	26
224	Things ain't what they used to be: Impact of a new definition of myocardial infarction. <i>American Heart Journal</i> , 2002, 144, 933-937.	2.7	26
225	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015, 170, 683-694.e3.	2.7	26
226	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 248-255.	1.6	26
227	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017, 187, 194-203.	2.7	26
228	Evolution of the definition of myocardial infarction: what are the implications of a new universal definition?. <i>Heart</i> , 2008, 94, 679-684.	2.9	25
229	Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. <i>European Heart Journal</i> , 2016, 37, ehv611.	2.2	25
230	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding. <i>Journal of the American College of Cardiology</i> , 2016, 67, 596-598.	2.8	25
231	Whole blood sequencing reveals circulating microRNA associations with high-risk traits in non-ST-segment elevation acute coronary syndrome. <i>Atherosclerosis</i> , 2017, 261, 19-25.	0.8	25
232	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 856-864.	2.9	25
233	The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolized: methods and design. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 241-246.	2.1	24
234	Usefulness of the presenting electrocardiogram in predicting myocardial salvage with thrombolytic therapy in patients with a first acute myocardial infarction. <i>European Heart Journal</i> , 2002, 23, 399-404.	2.2	24

#	ARTICLE	IF	CITATIONS
235	Comparison of case fatality in smokers and non-smokers after acute cardiac event. <i>BMJ: British Medical Journal</i> , 1997, 315, 992-993.	2.3	24
236	Should all occluded infarct-related arteries be opened?. <i>European Heart Journal</i> , 1997, 18, 1207-1209.	2.2	23
237	Future of reperfusion therapy for acute myocardial infarction. <i>Lancet, The</i> , 1999, 354, 695-697.	13.7	23
238	Avatar of the Universal Definition of Periprocedural Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1571-1574.	2.8	23
239	The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand (ANZACS-QI 55). <i>The Lancet Regional Health - Western Pacific</i> , 2020, 5, 100056.	2.9	23
240	Alirocumab after acute coronary syndrome in patients with a history of heart failure. <i>European Heart Journal</i> , 2022, 43, 1554-1565.	2.2	23
241	The Role of Lipoprotein-Associated Phospholipase A2 as a Marker and Potential Therapeutic Target in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2011, 13, 132-137.	4.8	22
242	The Prequel. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 142-145.	3.9	22
243	Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. <i>American Heart Journal</i> , 2014, 168, 76-87.e1.	2.7	22
244	Magnitude of Troponin Elevation and Long-Term Clinical Outcomes in Acute Coronary Syndrome Patients Treated With and Without Revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002314.	3.9	22
245	Incidence and Impact of Totally Occluded Culprit Coronary Arteries in Patients Presenting With Non- $\sigma$ ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2015, 115, 428-433.	1.6	22
246	Sudden Cardiac Death After Non- $\sigma$ ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 73.	6.1	22
247	Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by) Tj ETQq1 1 0.784314 2gBT /Ov		
248	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017, 245, 271-276.	1.7	22
249	FACTORS AFFECTING OUTCOME AFTER RECOVERY FROM MYOCARDIAL INFARCTION. <i>Annual Review of Medicine</i> , 1994, 45, 325-339.	12.2	21
250	Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. <i>Heart Rhythm</i> , 2007, 4, 308-313.	0.7	21
251	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. <i>American Heart Journal</i> , 2020, 222, 157-165.	2.7	21
252	Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 402-409.	2.9	20

#	ARTICLE	IF	CITATIONS
253	Comparison of Four Risk Scores for Contemporary Isolated Coronary Artery Bypass Grafting. <i>Heart Lung and Circulation</i> , 2014, 23, 469-474.	0.4	20
254	First and recurrent ischaemic heart disease events continue to decline in New Zealand, 2005-2015. <i>Heart</i> , 2018, 104, 51-57.	2.9	20
255	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 <sup>Â</sup> P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017, 63, 307-315.	3.2	19
256	All-Cause Mortality Following an Acute Coronary Syndrome: 12-Year Follow-Up of the Comprehensive 2002 New Zealand Acute Coronary Syndrome Audit. <i>Heart Lung and Circulation</i> , 2019, 28, 245-256.	0.4	19
257	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021, 44, 1219-1227.	8.6	19
258	Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease - A STABILITY Substudy. <i>Journal of the American Heart Association</i> , 2022, 11, e023667.	3.7	19
259	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 330-340.	11.4	19
260	Angioplasty versus bypass surgery. <i>Lancet</i> , 1995, 346, 1174-1175.	13.7	18
261	Documento de consenso de expertos. Tercera definici3n universal del infarto de miocardio. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 132.e1-132.e15.	1.2	18
262	Long-term outcomes for women versus men with unstable angina/nonST-segment elevation myocardial infarction managed medically without revascularization: Insights from the Targeted platelet Inhibition to clarify the Optimal strategy to medically manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015, 170, 695-705.e5.	2.7	18
263	Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. <i>Vascular Health and Risk Management</i> , 2007, 3, 425-30.	2.3	18
264	Relation of initial platelet counts to Thrombolysis In Myocardial Infarction-3 flow rates at 90 minutes after commencing fibrinolytic therapy in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 2002, 90, 54-57.	1.6	17
265	Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With NonST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014, 113, 936-944.	1.6	17
266	Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With NonST-Segment Elevation Acute Coronary Syndromes (from the Tj ETQq0 0 0.6gBT /Overlock 10 T		
267	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in NonST-SegmentElevation Acute Coronary Syndromes Clinical Trials. <i>Circulation</i> , 2016, 133, 1560-1573.	1.6	17
268	Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model. <i>International Journal of Cardiology</i> , 2017, 248, 361-368.	1.7	17
269	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005858.	2.2	17
270	Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: Insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. <i>American Heart Journal</i> , 2007, 154, 313-321.	2.7	16



#	ARTICLE	IF	CITATIONS
271	Will new higher-precision troponins lead to clarity or confusion?. <i>Current Opinion in Cardiology</i> , 2008, 23, 292-295.	1.8	16
272	Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. <i>PLoS ONE</i> , 2017, 12, e0182115.	2.5	16
273	Higher mortality in women undergoing coronary artery bypass grafting. <i>New Zealand Medical Journal</i> , 2013, 126, 25-31.	0.5	16
274	Aspirin or warfarin for non-rheumatic atrial fibrillation?. <i>Lancet, The</i> , 1994, 343, 683-684.	13.7	15
275	Effects of streptokinase in patients presenting within 6 hours of prolonged chest pain with ST segment depression.. <i>Heart</i> , 1995, 73, 500-505.	2.9	15
276	Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 777-788.	1.8	15
277	Electrocardiographic findings in cardiogenic shock, risk prediction, and the effects of emergency revascularization: Results from the SHOCK trial. <i>American Heart Journal</i> , 2004, 148, 810-817.	2.7	15
278	Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTEMI ACS: A subgroup analysis from the SYNERGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 928-935.	1.7	15
279	Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. <i>American Heart Journal</i> , 2016, 178, 1-8.	2.7	15
280	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1289-1297.	2.8	15
281	Clinical Trials of Direct Thrombin Inhibitors in Acute Ischaemic Syndromes. <i>Thrombosis and Haemostasis</i> , 1997, 78, 364-366.	3.4	15
282	Direct Antithrombins. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 249-257.	2.2	14
283	Patients with circumflex occlusions miss out on reperfusion. <i>Current Opinion in Cardiology</i> , 2012, 27, 327-330.	1.8	14
284	Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. <i>Heart</i> , 2015, 101, 279-286.	2.9	14
285	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 322-323.	2.8	14
286	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. <i>Cardiovascular Diabetology</i> , 2019, 18, 116.	6.8	14
287	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019, 208, 65-73.	2.7	14
288	Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements. <i>Scientific Reports</i> , 2020, 10, 6169.	3.3	14

#	ARTICLE	IF	CITATIONS
289	Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study. <i>Journal of the American Heart Association</i> , 2022, 11, e020745.	3.7	14
290	Comparative Tolerability Profiles of Thrombolytic Agents. <i>Drug Safety</i> , 1993, 8, 19-29.	3.2	13
291	Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO 2) Study. <i>Australian and New Zealand Journal of Medicine</i> , 1998, 28, 551-554.	0.5	13
292	The HERO-2 ECG sub-studies in patients with ST elevation myocardial infarction: Implications for clinical practice. <i>International Journal of Cardiology</i> , 2013, 170, 17-23.	1.7	13
293	Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 246-256.	1.0	13
294	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 <sup>AP</sup> )-TIMI 50. <i>Journal of the American Heart Association</i> , 2016, 5,	3.7	13
295	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , 2018, 202, 89-96.	2.7	13
296	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005635.	3.9	13
297	Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. <i>European Heart Journal</i> , 2022, 43, 148-149.	2.2	13
298	Lifting the smoke-screen: The enigma of better outcome in smokers after myocardial infarction. <i>American Journal of Cardiology</i> , 1995, 75, 278-279.	1.6	12
299	The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: Results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an international randomized Evaluation (STEEPLE) trial. <i>American Heart Journal</i> , 2009, 157, 125-131.	2.7	12
300	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 302	1.6	12
301	Thrombolytic Therapy in the Elderly. <i>Drugs and Aging</i> , 1996, 8, 237-244.	2.7	11
302	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 171, 25-32.	2.7	11
303	High flow oxygen and risk of mortality in patients with a suspected acute coronary syndrome: pragmatic, cluster randomised, crossover trial. <i>BMJ, The</i> , 2021, 372, n355.	6.0	11
304	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	3.1	11
305	Lack of relationship between obesity and mortality or morbidity after coronary artery bypass grafting. <i>New Zealand Medical Journal</i> , 2013, 126, 56-65.	0.5	11
306	The corrected TIMI frame count. The new gold standard?. <i>Australian and New Zealand Journal of Medicine</i> , 1998, 28, 569-573.	0.5	10

#	ARTICLE	IF	CITATIONS
307	Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 529-538.	3.3	10
308	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	10
309	Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. <i>American Heart Journal</i> , 2017, 188, 156-166.	2.7	10
310	Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2018, 196, 28-35.	2.7	10
311	Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 72, 37-43.	1.4	10
312	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 270, 96-101.	1.7	10
313	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management. <i>JAMA Cardiology</i> , 2021, 6, 1023.	6.1	10
314	We Must Use the Knowledge That We Have to Treat Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2004, 109, 698-700.	1.6	9
315	Strategies to minimize bleeding complications of percutaneous coronary intervention. <i>Current Opinion in Cardiology</i> , 2009, 24, 273-278.	1.8	9
316	Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER. <i>Journal of the American Heart Association</i> , 2014, 3, .	3.7	9
317	Prognostic performance of kinetic changes of high-sensitivity troponin T in acute coronary syndrome and in patients with increased troponin without acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 174, 524-529.	1.7	9
318	High-sensitivity Cardiac Troponin T in Stable Patients Undergoing Pharmacological Stress Testing. <i>Clinical Cardiology</i> , 2015, 38, 293-299.	1.8	9
319	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 1214-1226.	3.2	9
320	Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009609.	3.7	9
321	Pharmacoeconomic Aspects of Treatment of Acute Myocardial Infarction with Thrombolytic Agents. <i>Pharmacoeconomics</i> , 1993, 3, 192-204.	3.3	8
322	Allergic Reactions to Streptokinase. <i>BioDrugs</i> , 1994, 2, 415-420.	0.7	8
323	Is heparin of value in the management of acute myocardial infarction?. , 1997, 11, 111-119.		8
324	Relation of pathologic Q waves at presentation and time to streptokinase therapy with early changes in infarct-related artery flow and ventricular wall motion. <i>American Journal of Cardiology</i> , 2001, 88, 558-561.	1.6	8

#	ARTICLE	IF	CITATIONS
325	Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. <i>Journal of Hypertension</i> , 2002, 20, 2513-2517.	0.5	8
326	Efficacy and Safety of Vorapaxar in Non-“ST-“Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	8
327	Resolution of ST depression after fibrinolysis can be more important than resolution of ST elevation for many patients with inferior STEMIs. <i>International Journal of Cardiology</i> , 2015, 182, 232-234.	1.7	8
328	Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1667-1676.	2.9	8
329	Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
330	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
331	Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome. <i>Journal of Internal Medicine</i> , 2021, 290, 392-403.	6.0	8
332	Liver disease induced by perhexiline maleate. <i>Medical Journal of Australia</i> , 1982, 2, 9-10.	1.7	8
333	The All New Zealand Acute Coronary Syndrome Quality Improvement Programme: Implementation, Methodology and Cohorts (ANZACS-QI 9). <i>New Zealand Medical Journal</i> , 2016, 129, 23-36.	0.5	8
334	Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-Term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the <scp>TRILOGY ACS</scp> Trial. <i>Clinical Cardiology</i> , 2016, 39, 329-337.	1.8	7
335	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	7
336	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 158-165.	1.0	7
337	Sex And Prognostic Significance of Self-Reported Frailty in Non-“ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 430-437.	1.7	7
338	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021, 233, 92-101.	2.7	7
339	Cardiac death should be the primary endpoint for revascularization trials and meta-analyses. <i>European Heart Journal</i> , 2021, 42, 4697-4698.	2.2	7
340	Proposed new industry code on unhealthy food marketing to children and young people: will it make a difference?. <i>New Zealand Medical Journal</i> , 2017, 130, 94-101.	0.5	7
341	Type 2 MI and Myocardial Injury in the Era of High-sensitivity Troponin. <i>European Cardiology Review</i> , 2022, 17, e03.	2.2	7
342	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1842-1851.	1.8	7

#	ARTICLE	IF	CITATIONS
343	Remodelling of the heart after myocardial infarction. Australian and New Zealand Journal of Medicine, 1992, 22, 601-606.	0.5	6
344	Debate: Should the elderly receive thrombolytic therapy or primary angioplasty?. , 2000, 1, 150.		6
345	New ST-depression: an under-recognized high-risk category of "complete" ST-resolution after reperfusion therapy. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 210-221.	1.0	6
346	Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage and Preference) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 617		6
347	ST deviations and serial changes after reperfusion therapy in patients with inferior STEMIs: Relationship between inferior leads, medial chest leads and lateral leads. International Journal of Cardiology, 2015, 184, 348-349.	1.7	6
348	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	6
349	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. International Journal of Cardiology, 2019, 278, 217-222.	1.7	6
350	Adding Insult to Injury: Are There Treatments for Myocardial Injury and Type 2 Myocardial Infarction?. Journal of the American Heart Association, 2021, 10, e019796.	3.7	6
351	ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis. Expert Review of Cardiovascular Therapy, 2007, 5, 851-857.	1.5	5
352	A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. Personalized Medicine, 2010, 7, 319-325.	1.5	5
353	Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheterization and Cardiovascular Interventions, 2018, 92, E348-E355.	1.7	5
354	Cangrelor compared with clopidogrel in patients with prior myocardial infarction " Insights from the CHAMPION trials. International Journal of Cardiology, 2018, 250, 49-55.	1.7	5
355	Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. American Journal of Physiology - Renal Physiology, 2019, 316, G372-G386.	3.4	5
356	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006582.	2.2	5
357	Meta-Analysis of Bleeding Scores Performance for Acute Coronary Syndrome. Heart Lung and Circulation, 2020, 29, 1749-1757.	0.4	5
358	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. American Heart Journal, 2020, 225, 97-107.	2.7	5
359	Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events. Diabetologia, 2022, 65, 101-112.	6.3	5
360	LEFT VENTRICULAR FUNCTION FOLLOWING THROMBOLYTIC THERAPY FOR MYOCARDIAL INFARCTION. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 173-179.	1.9	4

#	ARTICLE	IF	CITATIONS
361	Thrombin Hypothesis: The TIMI 9B and GUSTO IIB Trials Have Successfully Disproven/Proven the Thrombin Hypothesis. , 1997, 4, 317-319.		4
362	New antiplatelet agents. Australian and New Zealand Journal of Medicine, 1998, 28, 558-564.	0.5	4
363	Effects of Dietary Factors on Lipoprotein-Associated Phospholipase A2 (Lp-PLA2). Current Atherosclerosis Reports, 2011, 13, 461-466.	4.8	4
364	Targeting Therapy to the Fibrin-Mediated Pathophysiology of Acute Coronary Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 516-523.	1.7	4
365	Republished: Clinical implications of the Third Universal Definition of Myocardial Infarction. Postgraduate Medical Journal, 2014, 90, 502-510.	1.8	4
366	Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American Heart Association, 2016, 5, .	3.7	4
367	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes. Coronary Artery Disease, 2018, 29, 469-476.	0.7	4
368	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clinical Cardiology, 2019, 42, 797-805.	1.8	4
369	Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome. Physiological Genomics, 2019, 51, 506-515.	2.3	4
370	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. American Heart Journal, 2019, 218, 57-65.	2.7	4
371	Deconstructing the Paradox of Smoking and Improved Short-Term Cardiovascular Outcomes After Myocardial Infarction. Journal of the American College of Cardiology, 2020, 75, 1755-1757.	2.8	4
372	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120010390.	3.9	4
373	Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. American Heart Journal, 2022, 251, 1-12.	2.7	4
374	B-type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart Disease. Journal of the American Heart Association, 2022, 11, .	3.7	4
375	Reperfusion injury - a reply to Keith Fox. Cardiovascular Research, 1992, 26, 660-661.	3.8	3
376	Effects of Thrombolytic Therapy on Left Ventricular Function and the Importance of Long-Term Patency of the Infarct-Related Artery. Clinical Science, 1995, 88, 21-24.	4.3	3
377	Acute myocardial infarction: Fibrinolytic therapy. Current Treatment Options in Cardiovascular Medicine, 2004, 6, 15-28.	0.9	3
378	Heart disease in Soweto: facing a triple threat. Lancet, The, 2008, 371, 876-877.	13.7	3

#	ARTICLE	IF	CITATIONS
379	Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes. <i>Coronary Artery Disease</i> , 2013, 24, 321-327.	0.7	3
380	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. <i>Heart</i> , 2016, 102, 1221-1229.	2.9	3
381	Health-related quality of life outcomes with prasugrel among medically managed non-â€‘ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>American Heart Journal</i> , 2016, 178, 55-64.	2.7	3
382	Discharge timing and outcomes after uncomplicated non-â€‘ST-segment elevation acute myocardial infarction. <i>American Heart Journal</i> , 2018, 201, 103-110.	2.7	3
383	Adjunctive antithrombotic therapy with primary percutaneous coronary intervention in ST elevation myocardial infarction: ATOLL in perspective. <i>European Heart Journal</i> , 2019, 40, e4-e7.	2.2	3
384	Clinically Important Improvements in Risk Assessment by Adding High-Sensitivity Troponin Level to Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020, 5, 1263.	6.1	3
385	Heparin use in acute coronary syndromes and cardiovascular interventions: habit or evidence based?. <i>European Heart Journal</i> , 2022, 43, 1008-1011.	2.2	3
386	Selecting a thrombolytic agent. <i>Cardiology Clinics</i> , 1995, 13, 347-54.	2.2	3
387	Clinical trials of direct thrombin inhibitors in acute ischaemic syndromes. <i>Thrombosis and Haemostasis</i> , 1997, 78, 364-6.	3.4	3
388	A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012. <i>New Zealand Medical Journal</i> , 2017, 130, 17-28.	0.5	3
389	Utilisation and maintenance of high-intensity statins following acute coronary syndrome and coronary angiography: opportunities to improve care (ANZACS-QI 26). <i>New Zealand Medical Journal</i> , 2020, 133, 21-40.	0.5	3
390	Heart failure: to digitalise or not? The view against. <i>Australian and New Zealand Journal of Medicine</i> , 1992, 22, 626-630.	0.5	2
391	Hirudin and Hirulog. <i>Australian and New Zealand Journal of Medicine</i> , 1993, 23, 769-770.	0.5	2
392	Ongoing clinical trials of anti-platelet agents in the management of acute ischaemic coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 1998, 7, 811-821.	4.1	2
393	Antithrombin agents as adjuncts to thrombolytic therapy. , 1999, 8, 159-166.		2
394	Direct thrombin inhibitors as adjuncts to thrombolytic therapy. <i>Current Cardiology Reports</i> , 1999, 1, 184-191.	2.9	2
395	Management of unstable angina. Guidelines â€‘ 2000. <i>Medical Journal of Australia</i> , 2001, 174, 423-424.	1.7	2
396	Facilitated percutaneous coronary intervention: Is this strategy ready for implementation?. <i>Current Cardiology Reports</i> , 2005, 7, 235-241.	2.9	2

#	ARTICLE	IF	CITATIONS
397	Enoxaparin: a perspective on its use for coronary artery disease. <i>Aging Health</i> , 2008, 4, 579-591.	0.3	2
398	Darapladib and its potential for plaque stabilization and prevention of cardiac events. <i>Clinical Lipidology</i> , 2010, 5, 465-476.	0.4	2
399	Response to Letter Regarding Article, "Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial". <i>Circulation</i> , 2010, 122, .	1.6	2
400	Antithrombotic therapy in ST-segment elevation myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 213-223.	1.8	2
401	Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 174, 90-95.	1.7	2
402	Impact of Nonculprit Vessel Myocardial Perfusion on Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 266-275.	2.9	2
403	Torrent of Troponin. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 435-438.	3.9	2
404	Post-operative aspartate aminotransferase levels independently predict mortality after isolated coronary artery bypass grafting. <i>IJC Metabolic &amp; Endocrine</i> , 2015, 6, 31-35.	0.5	2
405	Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. <i>American Heart Journal</i> , 2017, 188, 147-155.	2.7	2
406	Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease. <i>PLoS ONE</i> , 2018, 13, e0204352.	2.5	2
407	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1322-1329.	1.6	2
408	Waiting room computer tablets to improve health literacy and cardiovascular outcomes. <i>Heart</i> , 2021, 107, 1607-1608.	2.9	2
409	Glycoprotein IIb/IIIa Inhibitors. , 2008, , 65-86.		2
410	Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. , 2009, , 293-340.		2
411	Outcomes after ST-elevation myocardial infarction presentation to hospitals with or without a routine primary percutaneous coronary intervention service (ANZACS-QI 46). <i>New Zealand Medical Journal</i> , 2020, 133, 64-81.	0.5	2
412	Type 1, Type 2 Myocardial Infarction and Non-Ischemic Myocardial Injury"Opinion from the Front Lines. <i>American Journal of Medicine</i> , 2022, 135, 935-938.	1.5	2
413	Issues raised by GUSTO. <i>Australian and New Zealand Journal of Medicine</i> , 1993, 23, 739-741.	0.5	1
414	Coronary Artery Patency and Survival in Clinical Trials. <i>Journal of Thrombosis and Thrombolysis</i> , 1997, 4, 239-250.	2.1	1



#	ARTICLE	IF	CITATIONS
415	Thrombolytic eligibility. Australian and New Zealand Journal of Medicine, 1998, 28, 518-524.	0.5	1
416	Low molecular weight heparins in acute ischaemic syndromes. Australian and New Zealand Journal of Medicine, 1998, 28, 555-557.	0.5	1
417	HORIZONS trial: a step forward for primary percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2009, 7, 125-129.	1.5	1
418	Longitudinal study of a 9p21.3 SNP using a national electronic healthcare database. Personalized Medicine, 2010, 7, 361-369.	1.5	1
419	Rivaroxaban for the treatment of acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2013, 14, 917-927.	1.8	1
420	Reply to letter by Kirat and KÖsse: Maximizing information from a 12-lead electrocardiogram. International Journal of Cardiology, 2015, 197, 145-146.	1.7	1
421	Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 155-163.	1.0	1
422	Modest Improvement of Reperfusion Times Across Multiple ST-Segmentâ€Elevation Myocardial Infarction Networks With Rapid Care Process Implementation but no Effect on Mortality. Circulation: Cardiovascular Interventions, 2017, 10, e004769.	3.9	1
423	How Can You Have a Myocardial Infarction Without Significant Coronary Artery Disease? Whither MINOCA. Heart Lung and Circulation, 2018, 27, 649-651.	0.4	1
424	Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator: ANZACS-QI 24. Heart Lung and Circulation, 2020, 29, 824-834.	0.4	1
425	Impact of guideline-recommended versus non-guideline-recommended Î²-blocker and Doppler echocardiographic parameters on 1-year mortality in Thai ischemic cardiomyopathy patients: A prospective multicenter registry. BMC Cardiovascular Disorders, 2020, 20, 8.	1.7	1
426	Myocardial Infarction and Evolocumab. JAMA Cardiology, 2021, 6, 1220-1221.	6.1	1
427	Outcomes for Ximelagatran Compared with Warfarin According to INR Control: Results from SPORTIF III and V Atrial Fibrillation Trials.. Blood, 2005, 106, 902-902.	1.4	1
428	Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. Open Heart, 2018, 5, e000752.	2.3	1
429	Acute myocardial infarction: a true medical emergency. New Zealand Medical Journal, 1989, 102, 281-3.	0.5	1
430	PHARMAC and lack of funding for clopidogrel. New Zealand Medical Journal, 2005, 119, U1808.	0.5	1
431	The ATOLL trial of enoxaparin in primary percutaneous coronary intervention. European Heart Journal, 2010, 31, 2826-7.	2.2	1
432	Maori have worse outcomes after coronary artery bypass grafting than Europeans in New Zealand. New Zealand Medical Journal, 2013, 126, 12-22.	0.5	1

#	ARTICLE	IF	CITATIONS
433	30-day mortality after percutaneous coronary intervention in New Zealand public hospitals (ANZACS-QI 18). <i>New Zealand Medical Journal</i> , 2017, 130, 54-63.	0.5	1
434	Acute reperfusion for ST-elevation myocardial infarction in New Zealand (2015-2017): patient and system delay (ANZACS-QI 29). <i>New Zealand Medical Journal</i> , 2019, 132, 41-59.	0.5	1
435	Zooming in on the Enigmas of Type 2 Myocardial Infarction. <i>Circulation</i> , 2022, 145, 1201-1204.	1.6	1
436	BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk. <i>Heart</i> , 2022, 108, 1250-1252.	2.9	1
437	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. , 2013, , 332-397.		1
438	Door-to-needle times: Room for improvement and need for continuous audit. <i>EMA - Emergency Medicine Australasia</i> , 2000, 12, 91-94.	1.1	0
439	Elderly patients should not be denied fibrinolytic therapy. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 520-521.	3.3	0
440	Is there an acceptable ceiling for bleeding for an antithrombotic drug dose to be tested in a phase 3 trial?. <i>European Heart Journal</i> , 2009, 30, 2556-2557.	2.2	0
441	Coronary Artery Bypass Grafting. , 0, , 240-255.		0
442	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2884-2885.	2.8	0
443	P1226 Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
444	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y <sub>12</sub> Inhibitor Pretreatment. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007445.	3.9	0
445	In the transition from fibrinolysis to primary PCI, the HERO trials help refine STEMI ECG interpretation and Q wave analysis potentially alters future management. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 26-33.	1.0	0
446	Fibrinolysis for Acute Myocardial Infarction. <i>Fundamental and Clinical Cardiology</i> , 2009, , 651-666.	0.0	0
447	Management of ST-elevation myocardial infarction. , 2011, , 474-484.		0
448	Third universal definition of myocardial infarction. <i>Srce I Krvni Sudovi</i> , 2013, 32, 29-46.	0.1	0
449	Abstract 15281: Triglyceride Levels and Cardiovascular Outcomes After Acute Coronary Syndrome: Insights From the Odyssey Outcomes Trial. <i>Circulation</i> , 2020, 142, .	1.6	0
450	Research in the Antipodes at Green Lane. <i>European Heart Journal</i> , 2020, 41, 4081-4084.	2.2	0

#	ARTICLE	IF	CITATIONS
451	The management of myocardial infarction: an update. <i>Comprehensive Therapy</i> , 1990, 16, 11-5.	0.2	0
452	Thrombolytic therapy for acute myocardial infarction: where are we now? Where should we go?. <i>Chinese Medical Journal</i> , 1995, 108, 462-5.	2.3	0
453	Is thrombin a pharmacological target during reperfusion?. <i>Blood Coagulation and Fibrinolysis</i> , 1999, 10 Suppl 1, S55-7.	1.0	0
454	Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?. <i>Journal of Invasive Cardiology</i> , 2000, 12 Suppl A, 6A-13A.	0.4	0
455	Missed opportunities for better health outcomes in New Zealand. <i>New Zealand Medical Journal</i> , 2004, 117, U1002.	0.5	0
456	We should cap the health budget and spend more money on housing and food: NO. <i>Journal of Primary Health Care</i> , 2012, 4, 339-41.	0.6	0
457	Response to NZMJ editorial by Dr Elana Curtis entitled Deserving of more: framing of Māori inequities in cardiovascular care remain a challenge. <i>New Zealand Medical Journal</i> , 2013, 126, 132-3.	0.5	0
458	Management of suspected acute coronary syndrome patients admitted to cardiology or non-cardiology services at Auckland City Hospital: implications for future national data collection. <i>New Zealand Medical Journal</i> , 2018, 131, 30-39.	0.5	0
459	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011069.	3.9	0
460	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. <i>American Journal of Medicine</i> , 2022, , .	1.5	0
461	Common genetic variants do not predict recurrent events in coronary heart disease patients. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 96.	1.7	0